advertisement

---

1 General aspects (0)   1.1 Epidemiology (15)   1.2 Population genetics (3)   1.3 Pathogenesis (4)   1.4 Quality of life (6)   1.5 Glaucomas as cause of blindness (7)   1.6 Prevention and screening (2) 2 Anatomical structures in glaucoma (0)   2.1 Conjunctiva (3)   2.2 Cornea (20)   2.3 Sclera (3)   2.4 Anterior chamber angle (2)   2.5 Meshwork (0)     2.5.1 Trabecular meshwork (8)     2.5.2 Schlemms canal (0)     2.5.3 Scleral outlet channels (0)   2.6 Aqueous humor dynamics (0)     2.6.1 Production (0)     2.6.2 Outflow (1)       2.6.2.1 Trabecular meshwork (1)       2.6.2.2 Uveoscleral (0)     2.6.3 Compostion (6)   2.7 Episcleral veins and venous pressure (0)   2.8 Iris (2)   2.9 Ciliary body (1)   2.10 Lens (1)   2.11 Vitreous body (3)   2.12 Choroid, peripapillary choroid, peripapillary atrophy (0)   2.13 Retina and retinal nerve fibre layer (26)   2.14 Optic disc (12)   2.15 Optic nerve (3)   2.16 Chiasma and retrochiasmal central nervous system (0)   2.17 Stem cells (3)   2.20 Other (0) 3 Laboratory methods (0)   3.1 Microscopy (1)   3.2 Electron microscopy (2)   3.3 Immunohistochemistry (10)   3.4 Molecular genetics (1)     3.4.1 Linkage studies (4)     3.4.2 Gene studies (24)   3.5 Molecular biology incl. SiRNA (9)   3.6 Cellular biology (15)   3.7 Biochemistry (4)   3.8 Pharmacology (6)   3.9 Pathophysiology (5)   3.10 Immunobiology (1)   3.11 Pharmacogenetics (0)   3.12 Proteomics (3)   3.13 In vivo imaging (0)     3.13.1 Laser Scanning (0)       3.13.1.1 Confocal Scanning Laser Ophthalmoscopy (0)       3.13.1.2 Confocal Scanning Laser Polarimetry (0)     3.13.2 Optical Coherence Tomography (0)       3.13.2.1 Anterior Segment (0)       3.13.2.2 Posterior Segment (0)     3.13.3 RGC Imaging (0)     3.13.4 Other (0)   3.20 Other (0) 4 Tissue culture of ocular cells (0) 5 Experimental glaucoma; animal models (0)   5.1 Rodent (16)   5.2 Primates (0)   5.3 Other (15) 6 Clinical examination methods (0)   6.1 Intraocular pressure measurement; factors affecting IOP (0)     6.1.1 Devices, techniques (7)     6.1.2 Fluctuation, circadian rhythms (8)     6.1.3 Factors affecting IOP (8)   6.2 Tonography, aqueous flow measurement (see also 2.6) (1)   6.3 Biomicroscopy (slitlamp) (0)     6.3.1 Anterior segment (3)     6.3.2 Posterior segment (0)   6.4 Gonioscopy (0)   6.5 Ophthalmoscopy (0)   6.6 Visual field examination and other visual function tests (0)     6.6.1 Conventional manual (1)     6.6.2 Automated (11)     6.6.3 Special methods (e.g. color, contrast, SWAP etc.) (10)   6.7 Electro-ophthalmodiagnosis (9)   6.8 Photography (0)     6.8.1 Anterior segment (4)     6.8.2 Posterior segment (1)   6.9 Computerized image analysis (1)     6.9.1 Laser scanning (0)       6.9.1.1 Confocal Scanning Laser Ophthalmoscopy (14)       6.9.1.2 Confocal Scanning Laser Polarimetry (11)     6.9.2 Optical coherence tomography (0)       6.9.2.1 Anterior (4)       6.9.2.2 Posterior (11)     6.9.5 Other (4)   6.10 Fluorescein (ICG) angiography (0)     6.10.1 Anterior segment (0)     6.10.2 Posterior segment (1)   6.11 Bloodflow measurements (19)   6.12 Ultrasonography and ultrasound biomicroscopy (4)   6.13 Provocative tests (2)   6.19 Telemedicine (0)   6.20 Progression (8)   6.30 Other (2) 8 Refractive errors in relation to glaucoma (0)   8.1 Myopia (3)   8.2 Hypermetropia (0)   8.3 Contact lenses (0)   8.4 Refractive surgical procedures (2)   8.5 Other (0) 9 Clinical forms of glaucomas (0)   9.1 Developmental glaucomas (0)     9.1.1 Congenital glaucoma, Buphthalmos (9)     9.1.2 Juvenile glaucoma (10)     9.1.3 Syndromes of Axenfeld, Rieger, Peters, aniridia (0)     9.1.4 Other (0)   9.2 Primary open angle glaucomas (0)     9.2.1 Ocular hypertension (1)     9.2.2 Other risk factors for glaucoma (6)     9.2.3 Open angle glaucoma with elevated IOP (4)     9.2.4 Normal pressure glaucoma (9)   9.3 Primary angle closure glaucomas (0)     9.3.1 Acute primary angle closure glaucoma (pupillary block) (7)     9.3.2 Chronic primary angle closure glaucoma (pupillary block) (5)     9.3.3 Plateau iris syndrome (1)     9.3.4 Primary angle closure suspect (1)     9.3.5 Primary angle closure (4)     9.3.10 Other (0)   9.4 Glaucomas associated with other ocular and systemic disorders (0)     9.4.1 Steroid-induced glaucoma (8)     9.4.2 Glaucomas associated with disorders of the cornea, conjunctiva, sclera (0)       9.4.2.1 Iridocorneal endothelial syndrome (ICE, incl. irisatrophy) (0)       9.4.2.2 Posterior polymorphous dystrophy (0)       9.4.2.3 Fuchs' endothelial dystrophy (0)       9.4.2.5 Other (0)     9.4.3 Glaucomas associated with disorders of the iris and ciliary body (0)       9.4.3.1 Pigmentary glaucoma (2)       9.4.3.5 Other (2)     9.4.4 Glaucomas associated with disorders of the lens (0)       9.4.4.1 Exfoliation syndrome (14)       9.4.4.2 Glaucomas associated with cataracts (0)       9.4.4.3 Glaucomas associated with lens dislocation (3)       9.4.4.5 Other (0)     9.4.5 Glaucomas associated with disorders of the retina, choroid and vitreous (0)       9.4.5.1 Neovascular glaucoma (2)       9.4.5.5 Other (5)     9.4.6 Glaucomas associated with inflammation, uveitis (5)     9.4.7 Glaucomas associated with ocular trauma (1)     9.4.8 Glaucomas associated with intraocular tumors (0)     9.4.9 Glaucomas associated with elevated episcleral venous pressure (0)       9.4.10 Glaucomas associated with hemorrhage (3)     9.4.11 Glaucomas following intraocular surgery (0)       9.4.11.1 Ciliary block (malignant) glaucoma (0)       9.4.11.2 Glaucomas in aphakia and pseudophakia (3)       9.4.11.3 Epithelial, fibrous, and endothelial proliferation (0)       9.4.11.4 Glaucomas associated with corneal surgery (1)       9.4.11.5 Glaucomas associated with vitreoretinal surgery (0)     9.4.15 Glaucoma in relation to systemic disease (22)     9.4.20 Other (0) 10 Differential diagnosis e.g. anterior and posterior ischemic optic neuropathy (9) 11 Medical treatment (0)   11.1 General management, indication (4)   11.2 Cholinergic drugs (1)   11.3 Adrenergic drugs (0)     11.3.1 Epinephrine (0)     11.3.2 Thymoxamine, dapiprazole (0)     11.3.3 Apraclonidine, brimonidine (1)     11.3.4 Betablocker (8)     11.3.5 Other (0)   11.4 Prostaglandins (17)   11.5 Carbonic anhydrase inhibitors (1)     11.5.1 Systemic (1)     11.5.2 Topical (3)   11.6 Osmotic treatment (0)   11.7 Treatment of bloodflow (3)   11.8 Neuroprotection (19)   11.9 Gene therapy (2)   11.13 Combination therapy (1)     11.13.1 Betablocker and pilocarpine (0)     11.13.2 Betablocker and carbon anhydrase inhibitor (3)     11.13.3 Betablocker and brimonidine (1)     11.13.4 Betablocker and prostaglandin (1)     11.13.5 Other (2)   11.14 Investigational drugs; pharmacological experiments (14)   11.15 Other drugs in relation to glaucoma (0)   11.16 Vehicles, delivery systems, pharmacokinetics, formulation (6)   11.17 Cooperation with medical therapy e.g. persistency, compliance, adherence (3)   11.20 Other (3) 12 Surgical treatment (0)   12.1 General management, indication (3)   12.2 Laser iridotomy (4)   12.3 Laser iridoplasty (2)   12.4 Laser trabeculoplasty and other laser treatment of the angle (4)   12.7 Surgical iridectomy (0)   12.8 Filtering surgery (0)     12.8.1 Without tube implant (9)     12.8.2 With tube implant or other drainage devices (8)     12.8.3 Non-perforating (4)     12.8.4 Using laser (0)     12.8.5 Other (2)     12.8.10 Woundhealing antifibrosis (17)     12.8.11 Complications, endophthalmitis (3)   12.9 Trabeculotomy, goniotomy (0)   12.10 Cyclodestruction (3)   12.11 Cyclodialysis (2)   12.12 Cataract extraction (0)     12.12.1 Intracapsular (0)     12.12.2 Extracapsular (1)     12.12.3 Phacoemulsification (8)   12.14 Combined cataract extraction and glaucoma surgery (0)     12.14.1 Intracapsular (0)     12.14.2 Extracapsular (1)     12.14.3 Phacoemulsification (7)   12.15 Capsulotomy (0)   12.16 Vitrectomy (0)   12.17 Anesthesia (0)   12.20 Other (3) 13 Therapeutic prognosis and outcome (0)   13.1 Prognostic factors (1)   13.2 Outcome (0)     13.2.1 IOP (1)     13.2.2 Visual field (0)       13.2.2.1 Progression (0)       13.2.2.2 Improvement (0)     13.2.3 Other (0) 14 Costing studies; pharmacoeconomics (2) 15 Miscellaneous (8)

---

Abstract #21650 Published in IGR 10-3

Protective effect of adenovirus-mediated pigment epithelium-derived factor on retinal ischemia-reperfusion injury in rats

Xu X; Liu Z-L; Zhang H; Shao D; Cao J
International Journal of Ophthalmology 2008; 8: 899-902

---

AIM: To examine the protective effects and mechanism of adenovirally delivered pigment epithelium derived factor (Ad-PEDF) on experimental retinal ischemia reperfused injury (RIR) in rats. METHODS: RIR was induced in 96 adult rats by increasing intraocular pressure (IOP) via an intracameral infusion. All of the rats were divided into four groups: normal control group; RIR group; RIR + Ad-PEDF treatment group and RIR Ad-CMV control group. The groups were subdivided into groups of 12 hours, 24 hours, 72 hours and 168 hours after reperfusion randomly. The neuroprotective effects of Ad-PEDF were evaluated by determining the preservation of the inner retina thickness and the cell counts in the retinal ganglion cell layer by HE staining method. The levels of retinal ganglion cell (RGC) apoptosis were measured using the TdT-dUTP terminal nick-end labeling (TUNEL) method. RESULTS: Significant ameliorative effect on the thickness of the inner retina was observed in Ad-PEDF treated eyes. More cells in the RGC layer were retained in the Ad-PEDF treated eyes than untreated eyes. There were fewer apoptotic cells in the RGC layer in Ad-PEDF injected eyes than in untreated eyes. These results were statistically significant (P < 0.05, respectively). CONCLUSION: Intravitreal injection of Ad-PEDF protected the inner retina and the cells in the RGC layer of eyes after ischemia-reperfusion injury. Intravitreal injection of Ad-PEDF moderately protected rat retina from ischemia-reperfusion injury possibly by preventing apoptosis in retinal cells. LA: Chinese

Dr. X. Xu, Department of Ophthalmology, Hospital of China Medical University, Shenyang 110001 Liaoning Province, China. suxiexu73@sina.com

---

Classification:

11.9 Gene therapy (Part of: 11 Medical treatment)
5.1 Rodent (Part of: 5 Experimental glaucoma; animal models)
11.8 Neuroprotection (Part of: 11 Medical treatment)

---

• ← Previous
• Next →

---